Current Progresses on Nanodelivery Systems for the Treatment of Neuropsychiatric Diseases: Alzheimer’s and Schizophrenia

Author(s): A.C. Silva, E. González-Mira, J.M. Sousa Lobo, M.H. Amaral

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 41 , 2013

Become EABM
Become Reviewer
Call for Editor


Currently Alzheimer’s disease and schizophrenia are both well-established neuropsychiatric diseases. Nonetheless, the treatment of these disorders is not unanimous and fully effective. As a consequence, several approaches have been studied to improve patient’s conditions. In this context, the development of new drug nanodelivery systems to increase drug bioavailability and reduce adverse effects has been claimed as a good option. Among these systems we focus on the ones that seem to be most promising, such as lipidbased systems (e.g. liposomes, nanoemulsions and lipid nanoparticles), drug nanocrystals, polymeric nanoparticles and micelles. Moreover, the application of these systems by means of alternative administration routes is also discussed.

Regardless of the satisfactory results and the associated progresses that have been done in the last years, more studies are required to quickly licence the application of drug nanodelivery systems in human medicines.

Keywords: Alzheimer’s, schizophrenia, liposomes, nanoemulsions, lipid nanoparticles, drug nanocrystals, polymeric nanoparticles, micelles.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 19 December, 2013
Page: [7185 - 7195]
Pages: 11
DOI: 10.2174/138161281941131219123329
Price: $65

Article Metrics

PDF: 27